Cereno Scientific to present preclinical data for the drug candidate CS585 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH 2023 Congress)
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on the preclinical drug candidate CS585 has been accepted as an oral presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH 2023 Congress), in Montreal, Canada on June 24-28, 2023. The abstract titled “CS585 is a novel and highly selective IP receptor agonist for prevention of thrombosis” will be presented by Dr. Michael Holinstat, lead of Cereno’s development programs at University